| (USD) | Jun 2024 | Q/Q |
|---|---|---|
| Revenue | 22.3MM | +43% |
| Gross Profit | 11.7MM | - |
| Cost Of Revenue | 10.6MM | - |
| Operating Income | -56MM | -12% |
| Operating Expenses | 67.8MM | - |
| Net Income | -53MM | -16% |
| R&D | 48.9MM | -11% |
| G&A | 18.9MM | +3% |
| Interest Expense | 449K | -77% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. Last year, the ecosystem reached a valuation of $1.55 trillion. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion. Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for soluti
The average of price targets set by Wall Street analysts indicates a potential upside of 234.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
REGENXBIO ( NASDAQ:RGNX ) Second Quarter 2024 Results Key Financial Results Revenue: US$22.3m (up 12% from 2Q 2023...
Regenxbio (RGNX) delivered earnings and revenue surprises of 18.60% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ROCKVILLE, Md. AP) — Regenxbio Inc. RGNX) on Thursday reported a loss of $53 million in its second quarter.
REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the second quarter ending June 30, 2024. Recent operational highlights, including acceleration of the late-stage pipeline, support meaningful value generation from the Company's leading portfolio of AAV Therapeutics.
REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 1 to 11 years old.
On July 29, 2024, Curran Simpson, CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 9,648 shares of the company, according to the SEC Filing. Regenxbio Inc (NASDAQ:RGNX) is a biotechnology firm focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. Over the past year, the insider transaction history at Regenxbio Inc shows a total of 12 insider sells and no insider buys.
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights.